Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, CFO and Treasurer | January 31, 2024 | February 02, 2024 |
| AlerisLife Inc.NASDAQ:FVE · Entity 115386 | Chief Accounting Officer | December 14, 2020 | December 16, 2020 |
| Pear Therapeutics, Inc.PEAR · Entity 114512 | VP, Chief Accounting Officer | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 519,300 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 149,300 · Balance 519,300 F1: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2034-01-31 | Direct | 224,000 |
Reported balance
After 2024-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-31 · Grant · Acquired 224,000 · Balance 224,000 F2: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
AlerisLife Inc.
Report date December 14, 2020 · Filed December 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,500 |
Reported balance
After 2020-12-14 transaction · row 1
1 source rowRow 1 · 2020-12-14 · Grant · Acquired 2,500 · Balance 2,500 F1: Transaction reported is grant of shares pursuant to issuer's equity compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction reported is grant of shares pursuant to issuer's equity compensation plan.
Pear Therapeutics, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 199,864 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 199,864 · Balance 199,864 F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 40,000 |
Reported balance
After 2023-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-16 · Grant · Acquired 40,000 · Balance 40,000 F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock.
F2: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 224,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-24-000975 · primarydocument.xml · derivative · entry 2 Snow Ellen · CIK 0001786643 · SVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,000 Underlying: Common Stock · 224,000 shares Expires 2034-01-31 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 149,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000975 · primarydocument.xml · nonDerivative · entry 1 Snow Ellen · CIK 0001786643 · SVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519,300 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:35 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 560,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001562180-23-006088 · primarydocument.xml · derivative · entry 2 Snow Ellen · CIK 0001786643 · SVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2033-07-31 F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:35 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 370,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-006088 · primarydocument.xml · nonDerivative · entry 1 Snow Ellen · CIK 0001786643 · SVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,000 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the RSUs will vest upon each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:14 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004045 · form4.xml · derivative · entry 2 Snow Ellen · CIK 0001786643 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:14 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 199,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004045 · form4.xml · derivative · entry 1 Snow Ellen · CIK 0001786643 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,864 Underlying: Class A Common Stock · 199,864 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% on February 15, 2024; 33% on February 15, 2025; and 34% on February 15, 2026. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:08 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | SaleClass A Common Stock | 8,027 | $1.13 | $9,070.51 |
DisclosureSEC source: 0001062993-23-001326 · form4.xml · nonDerivative · entry 1 Snow Ellen · CIK 0001786643 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,318 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.03 to $1.335, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 17:02 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | Exercise / conversionRestricted Stock Units · Derivative | 20,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001037 · form4.xml · derivative · entry 2 Snow Ellen · CIK 0001786643 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,256 Underlying: Common Stock · 20,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F3 · derivative.exercise_date: The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025. F3 · derivative.expiration_date: The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025. Read SEC document |
| January 14, 2023 Filed Jan 18, 2023 17:02 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | Exercise / conversionCommon Stock | 20,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001037 · form4.xml · nonDerivative · entry 1 Snow Ellen · CIK 0001786643 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11,025 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 30, 2022. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:45 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantRestricted Stock Units · Derivative | 61,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004988 · form4.xml · derivative · entry 1 Snow Ellen · CIK 0001786643 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,576 Underlying: Common Stock · 61,576 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PEAR common stock. F2 · derivative.exercise_date: The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025. F2 · derivative.expiration_date: The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 17:26 UTC | Pear Therapeutics, Inc. PEAR · Entity 114512 | GrantStock Option (Right to Buy) · Derivative | 265,034 | Not disclosed Strike: $1.40 | Not disclosed |
DisclosureSEC source: 0001062993-21-012401 · form4.xml · derivative · entry 1 Snow Ellen · CIK 0001786643 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,034 Underlying: Common Stock · 265,034 shares Expires 2031-04-28 F2 · price: Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 180,000 shares of common stock of Private Pear for $2.06 per share. F1 · derivative.exercise_date: 25% of the shares underlying the option vested or shall vest on March 29, 2022 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:16 UTC | AlerisLife Inc. NASDAQ:FVE · Entity 115386 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-136291 · tm2038461-4_4seq1.xml · nonDerivative · entry 1 Snow Ellen · CIK 0001786643 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: Transaction reported is grant of shares pursuant to issuer's equity compensation plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.